Article Sidebar

Submitted
Jun 23, 2025
Published
Jun 23, 2025
Download
PDF
Statistic
Read Counter : 23 Download : 8

Main Article Content

Abstract

Glaucoma is caused by high pressure inside the eye. Glaucoma is the leading cause of irreversible Glaucoma is a group of diseases that damage the optic nerve, the main nerve that leads from the eye to the brain. This damage is usually blindness worldwide. There are two main types of glaucoma: primary open-angle glaucoma and primary angle-closure glaucoma. Early detection and treatment are important to prevent vision loss from glaucoma. There is growing interest in the potential of nutraceuticals for glaucoma management. Nutraceuticals are a class of dietary supplements that are believed to offer health benefits beyond basic nutrition. While they are not a replacement for conventional glaucoma treatment, some nutraceuticals show promise as complementary therapies. Here are some of the nutraceuticals that have been studied in relation to glaucoma: Ginkgo biloba: This herb is one of the most studied nutraceuticals for glaucoma. It has antioxidant and neuroprotective properties, which may help to protect retinal ganglion cells from damage. Some studies have shown that ginkgo biloba may be helpful in slowing the progression of glaucoma, although more research is needed. Coenzyme Q10 (CoQ10): CoQ10 is an antioxidant that is important for mitochondrial function. Mitochondria are the powerhouses of cells, and they are essential for the health of retinal ganglion cells. Studies have shown that CoQ10 may help to improve blood flow to the optic nerve and protect retinal ganglion cells from damage. Magnesium: Magnesium is a mineral that is involved in many important cellular processes, including blood flow regulation and nerve function. Some studies have shown that magnesium may help to lower intraocular pressure (IOP), a major risk factor for glaucoma

Keywords

Glaucoma disease etiology risk factors symptoms pathophysiology treatment and relevant nutraceuticals

Article Details

How to Cite
Shaik parveen, Thadakokkula Keerthana, Ravulapally Ashwitha, & Gachubai Varshini. (2025). Nutraceuticals -A Miracle Cure For Glaucoma. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(2), 433-448. Retrieved from https://ijrpp.com/ijrpp/article/view/685
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Cook C, Foster P. Epidemiology of glaucoma: what's new? Can J Ophthalmol. 2012
  2. 2. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. glaucoma 2017
  3. 3. Bailey JN, Loomis SJ, Kang JH etal., Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016 Feb;48(2):189-94.
  4. 4. Turalba AV, Chen TC. Clinical and genetic characteristics of primary juvenile-onset open-, angle glaucoma (JOAG). Semin Ophthalmol. 2008 Jan-Feb;23(1):19-25
  5. 5. Izquierdo NJ, Traboulsi EI, Enger C, Maumenee IH. Glaucoma in the Marfan syndrome. Trans Am Ophthalmol Soc. 1992;90:111-7; discussion 118-22.
  6. 6. Kiuchi Y, Kanamoto T, Nakamura T. Double hump sign in indentation gonioscopy is correlated with presence of plateau iris configuration regardless of patent iridotomy. J Glaucoma. 2009 Feb;18(2):161-4.
  7. 7. Laganowski HC, Kerr Muir MG, Hitchings RA. Glaucoma and the iridocorneal endothelial syndrome. Arch Ophthalmol. 1992 Mar;110(3):346-50.
  8. 8. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001 Oct;108(10):1767-76; quiz1777, 1800.
  9. 9. Perez RN, Phelps CD, Burton TC. Angel-closure glaucoma following scleral buckling operations. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 Mar-Apr;81(2):247-52.
  10. 10. Aminlari A, East M, Wei W, Quillen D. Topiramate induced acute angle closure glaucoma. Open Ophthalmol J. 2008 Mar 28;2:46-7.
  11. 11. Plateroti P, Plateroti AM, Abdolrahimzadeh S, Scuderi G. Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Review of the Literature with Updates on Surgical Management. J Ophthalmol. 2015;2015:370371.
  12. 12. Roll P, Benedikt O. [Electronmicroscopic studies of the trabecular meshwork in corticosteroid glaucoma]. Klin Monbl Augenheilkd. 1979 Mar;174(3):421-8.
  13. 13. Calafiore S, Perdicchi A, Scuderi G, Contestabile MT, Abdolrahimzadeh S, Recupero SM. Glaucoma Management in Carotid Cavernous Fistula. Case Rep Ophthalmol. 2016 May-Aug;7(2):296-302.
  14. 14. Choong YF, Irfan S, Menage MJ. Acute angle closure glaucoma: an evaluation of a protocol for acute treatment. Eye (Lond). 1999 Oct;13 ( Pt 5):613-6.
  15. 15. POSNER A, SCHLOSSMAN A. Further observations on the syndrome of glaucomatocyclitic crises. Trans Am Acad Ophthalmol Otolaryngol. 1953 Jul-Aug;57(4):531-6.
  16. 16. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Resnikoff S, Taylor HR., Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013 Dec;1(6):e339-49.
  17. 17. Heijl A, Bengtsson B, Hyman L, Leske MC., Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009 Dec;116(12):2271-6.
  18. 18. Arora T, Bali SJ, Arora V, Wadhwani M, Panda A, Dada T. Diurnal versus office-hour intraocular pressure fluctuation in primary adult onset glaucoma. J Optom. 2015 Oct-Dec;8(4):239-43.
  19. 19. Levene RZ. Low tension glaucoma: a critical review and new material. Surv Ophthalmol. 1980 May-Jun;24(6):621-64.
  20. 20. Drance SM, Sweeney VP, Morgan RW, Feldman F. Factors involved in the production of low tension glaucoma. Can J Ophthalmol. 1974 Oct;9(4):399-403.
  21. 21. Jonas JB, Fernández MC, Stürmer J. Pattern of glaucomatous neuroretinal rim loss. Ophthalmology. 1993 Jan;100(1):63-8.
  22. 22. Moghimi S, Ramezani F, He M, Coleman AL, Lin SC. Comparison of Anterior Segment-Optical Coherence Tomography Parameters in Phacomorphic Angle Closure and Acute Angle Closure Eyes. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7611-
  23. 23. Thomas R, George R, Parikh R, Muliyil J, Jacob A. Five year risk of progression of primary angle closure suspects to primary angle closure: a population based study. Br J Ophthalmol. 2003 Apr;87(4):450-4.
  24. 24. Craven ER, Katz LJ, Wells JM, Giamporcaro JE., iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012 Aug;38(8):1339-45.
  25. 25. Anderson DR., Normal Tension Glaucoma Study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003 Apr;14(2):86-90.
  26. 26. Wright C, Tawfik MA, Waisbourd M, Katz LJ. Primary angle-closure glaucoma: an update. Acta Ophthalmol. 2016 May;94(3):217-25.
  27. 27. Bai HQ, Yao L, Wang DB, Jin R, Wang YX. Causes and treatments of traumatic secondary glaucoma. Eur J Ophthalmol. 2009 Mar-Apr;19(2):201-6.
  28. 28. Leibowitz HM. The red eye. N Engl J Med. 2000 Aug 03;343(5):345-51.
  29. 29. Greenfield DS. Glaucomatous versus nonglaucomatous optic disc cupping: clinical differentiation. Semin Ophthalmol. 1999 Jun;14(2):95-10.
  30. 30. Pasol J. Neuro-ophthalmic disease and optical coherence tomography: glaucoma look-alikes. Curr Opin Ophthalmol. 2011 Mar;22(2):124-32.
  31. 31. Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):853-9.
  32. 32. Pelčić G, Ljubičić R, Barać J, Biuk D, Rogoić V. Glaucoma, depression and quality of life: multiple comorbidities, multiple assessments and multidisciplinary plan treatment. Psychiatr Danub. 2017 Sep;29(3):351-359
  33. 33. Gallo Afflitto G, Aiello F, Cesareo M, Nucci C. Primary Open Angle Glaucoma Prevalence in Europe: A Systematic Review and Meta-Analysis. J Glaucoma. 2022 Oct 01;31(10):783-788.
  34. 34. Singh K, Bhushan P, Mishra D, Kaur K, Gurnani B, Singh A, Pandey S. Assessment of optic disk by disk damage likelihood scale staging using slit-lamp biomicroscopy and optical coherence tomography in diagnosing primary open-angle glaucoma. Indian J Ophthalmol. 2022 Dec;70(12):4152-4157.
  35. 35. Ezinne NE, Shittu O, Ekemiri KK, Kwarteng MA, Tagoh S, Ogbonna G, Mashige KP. Visual Impairment and Blindness among Patients at Nigeria Army Eye Centre, Bonny Cantonment Lagos, Nigeria. Healthcare (Basel). 2022 Nov 18;10(11)
  36. 36. Parab A, Kavitha S, Odayappan A, Venkatesh R. Clinical and demographic profile of patients less than 40 years of age presenting to glaucoma services at a tertiary care eye hospital in South India. Indian J Ophthalmol. 2022 Dec;70(12):4186-4192.
  37. 37. Wagner IV, Stewart MW, Dorairaj SK. Updates on the Diagnosis and Management of Glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022 Dec;6(6):618-635.
  38. 38. Foster PJ, Luben R, Khawaja AP. Association, Risk, and Causation-Examining the Role of Systemic Medications in the Onset of Acute Angle-Closure Episodes. JAMA Ophthalmol. 2022 Nov 01;140(11):1064-1065.
  39. 39. Xu KM, Cho R, Chan TYB. Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension. Clin Ophthalmol. 2022;16:2385-23(10)
  40. 40. Gosling D, Meyer JJ. StatPearls... StatPearls Publishing; Treasure Island (FL): Dec 12, 2022. Normal Tension Glaucoma.
  41. 41. Mahabadi N, Foris LA, Tripathy K. StatPearls . StatPearls Publishing; Treasure Island (FL): Aug 22, 2022. Open Angle Glaucoma.
  42. 42. Khazaeni B, Zeppieri M, Khazaeni L. StatPearls . StatPearls Publishing; Treasure Island (FL): Nov 26, 2023. Acute Angle-Closure Glaucoma.